Allergan (NYSE:AGN) is one of the many biotech stocks that has been beaten down in the last one and a half year. In this article I will indicate 4 reasons why I think the company and the stock can perform well in the future.
Reason #1: Diversified sources of revenue and rich pipeline
One of the characteristics that I like in Allergan is its rich portfolio of drugs. As we can see....More>>>
Related MGM Vegas Strip Revenue Slumps In July Callaway's Stake In TopGolf Nearly Doubles In A Year, Now Worth $400 Million This Casino Giant Breaks Out As Typhoon Can't Stop Macau Gaming (Investor’s Business Daily)
Related SEAS Resurrected: Zombie Headlines And How Old News Can Move Stocks ....More>>>
TripAdvisor (TRIP) tumbled to the bottom of the S&P 500 today, a reversal of yesterday’s big gain following the news thatExpedia (EXPE) would participate in its Instant Booking program.
Agence France-Presse/Getty Images
TripAdvisordropped 5.1% to $46.28 today, while the S&P 500 declined 0.3% to 2,265.18.
In a note published yesterday, SunTrust Robinson Humphrey’s....More>>>
Puma Biotechnology (NASDAQ:PBYI) ended the day down 13.8% after Roche (NASDAQOTH:RHHBY) reported that its rival breast cancer drug, Perjeta, had passed its phase 3 trial, dubbed “Aphinity.”
Image source: Getty Images.
In Roche’s trial, patients either took Perjeta and Herceptin with chemotherapy or just Herceptin with chemotherapy,....More>>>
One of the smaller details of Trumpcare, the redacted version of Obamacare, is the elimination of a tax imposed on manufacturers of medical devices. While the fate of pre-existing conditions has been hogging the spotlight in recent days, this particular tax and its future could have an impact on companies like Ventripoint Diagnostics (OTCMKTS: VPTDF TSE:VPT), and other small cap biotech....More>>>
Employees stand outside the new Amazon Go grocery store in Seattle, Washington, U.S., on Tuesday, Dec. 6, 2016. Amazon.com Inc. unveiled technology that will let shoppers grab groceries without having to scan and pay for them — in one stroke eliminating the checkout line. Photographer: David Ryder/Bloomberg
There’s nothing wrong with profit or efficiency. If you’re in business,....More>>>
Healthcare spending is on track to make up nearly 20% of U.S. GDP by 2025, according to the U.S. Centers for Medicare & Medicaid Services (CMS).
That’s one of the reasons we expect the biotech stock we’re showing you today to double in price by 2020.
Another catalyst for this top biotech stock is the aging baby boomer generation. There are currently 76.5 million....More>>>
Starting with a simple tweet on September 21st, 2015, Hillary Clinton has been pummeling Biotech stocks since her Presidential Campaign first began. In fact, Clinton has caused dramatic drops in the iShares Nasdaq Biotechnology ETF (IBB) at least three times in the past 14 months. The thought of Clinton winning the presidency, and the corresponding assault on the Biotech sector,....More>>>
Its been said of biotech that its the wild west of the investment world. There may be gold in the hills but you better have a good map and a keen eye to find it. One such company that is shimmering of late is Ventripoint Diagnostics (OTC: VPTDF), the Toronto, Ontario based developer of medical devices. With its new cardiac imaging device, the VMS Plus , Ventripoint is changing the way....More>>>
Like most of you, I don’t like to lose money. So you might be wondering why I was so quick to scoop up more shares of Gilead Sciences (NASDAQ:GILD) stock after its latest earnings report. After all, management shared a forecast for 2017 hepatitis C antiviral sales 39% lower than 2016 figures, and that’s at the high end of the provided range.
Before you assume I’ve completely....More>>>